Treatment Strategies for Acute Promyelocytic Leukemia

Acute promyelocytic leukaemia (APL) is a distinct subtype of acute myeloid leukaemia driven by the PML-RARA fusion oncoprotein, which blocks differentiation of myeloid precursors at the promyelocyte stage. The advent of targeted differentiation therapy has transformed APL from a near-universally fatal disease to one of the most curable forms of acute leukaemia. Current standard-of-care regimens stratify patients by presenting white blood cell count and other risk factors into low-, intermediate- and high-risk groups. Low-risk patients often receive a chemotherapy-free combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which synergise to degrade PML-RARA and restore normal myeloid maturation with high rates of molecular remission. Intermediate- and high-risk patients are treated with ATRA plus ATO alongside anthracycline or cytarabine-based chemotherapy to reduce the risk of early haemorrhagic complications and to achieve rapid cytoreduction. Supportive measures, including aggressive management of coagulopathy and prophylaxis against differentiation syndrome, are essential to minimise early mortality. Molecular monitoring of PML-RARA transcripts guides the duration of consolidation and maintenance therapy, reducing overtreatment and improving long-term outcomes. Emerging approaches aim to refine risk assignment through genomic profiling, to prevent relapse in high-risk subsets and to develop novel agents for patients intolerant of standard differentiation therapy.

Research from Nature Portfolio

Recent studies have employed integrated multi-omics and advanced computation to dissect how PML-RARA influences gene regulation in APL cells. High-resolution chromatin profiling combined with machine learning has revealed that PML-RARA binds diverse regulatory elements, exerting both repressive and activating effects on target genes depending on local chromatin context. This work has uncovered distinct transcriptional signatures associated with therapeutic response and has identified novel co-factors that modulate retinoic acid-driven differentiation. Such insights not only deepen mechanistic understanding of PML-RARA biology but also highlight candidate molecular targets for overcoming resistance to ATRA and ATO in refractory or relapsed disease.

Treatment Strategies for Acute Promyelocytic Leukemia publication trend

The graph below shows the total number of articles in treatment strategies for acute promyelocytic leukemia across all publications each year (not limited to Nature Index journals).

Technical terms

PML-RARA fusion protein: Oncogenic product of t(15;17) translocation that aberrantly represses retinoic acid target genes and blocks myeloid differentiation.

All-trans retinoic acid (ATRA): Vitamin A derivative that binds RARA to relieve transcriptional repression by PML-RARA and induce leukaemic cell differentiation.

Arsenic trioxide (ATO): Inorganic compound that promotes degradation of PML-RARA through sumoylation-dependent pathways and induces apoptosis of APL cells.

Differentiation syndrome: Potentially life-threatening inflammatory response during induction therapy characterised by fever, respiratory distress, capillary leak and organ dysfunction, requiring prompt corticosteroid treatment.

References

1. Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia. Nature Communications (2023).
2. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal (2015).
3. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer Journal (2021).
4. THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.. Mediterranean Journal of Hematology and Infectious Diseases (2011).